Clinical Trials Logo

Clinical Trial Summary

We hypothesize that the miRNA expression in subjects with nasal polyps and Aspirin-exacerbated respiratory disease (AERD) differs from the miRNA expressed in subjects with nasal polyps but without Aspirin-exacerbated respiratory disease (AERD).


Clinical Trial Description

Nasal epithelial tissue will be collected from the inferior nasal turbinates of ten subjects with nasal polyps and AERD disease and from the inferior turbinates of ten subjects with nasal polyps but without AERD. A rhinoprobeā„¢ will be used to collect this epithelial tissue. These samples will be analyzed by miRNA assay to determine if there is a difference in mircroRNA expression between the two subject groups. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01631773
Study type Observational
Source University of South Florida
Contact
Status Completed
Phase N/A
Start date August 2011
Completion date June 2012

See also
  Status Clinical Trial Phase
Completed NCT03595488 - Dupilumab for Aspirin-exacerbated Respiratory Disease Phase 2
Enrolling by invitation NCT03627481 - Sleep Quality After Nasosinusal Surgery in AERD Patients N/A
Recruiting NCT05672030 - Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP
Completed NCT03849625 - Characteristics of Patients Diagnosed With NSAID Sensitivity in Thailand
Recruiting NCT05031455 - Mechanisms of Dupilumab in AERD Phase 2
Active, not recruiting NCT03973749 - Effects of a High or Low Salycilate Diet on Urinary LTE4 and Clinical Features in AERD N/A
Recruiting NCT04147013 - Effect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients With CRS Phase 4
Recruiting NCT05575037 - Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease Phase 2
Completed NCT03326063 - Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban Phase 2